ARTICLE SUMMARY:
Proper monitoring during hemodialysis is crucial for catching complications early before they develop into more costly and health-threatening situations, yet most clinicians lack the time to implement it consistently. PatenSee’s contact-free solution aims to improve monitoring protocols without adding to the clinical workload.
Israel’s MEDX Xelerator is responsible for launching many of the country’s most innovative medtech start-ups over the last seven years. (See “MEDX Xelerator’s Strategy for Seeding Device Companies: Intensive Collaboration,” MedTech Strategist, September 15, 2022.) Led by Shai Policker, the early-stage incubator offers its portfolio companies clinical support from Sheba Medical Center as well as financial backing and other benefits. Policker, whose background is in electrical engineering and business, has been involved in the start-up space for more than two decades, focusing his efforts on commercialization, clinical trial operations, and R&D, and he now serves as interim CEO of PatenSee. Originating from hemodialysis providers’ expressed need for improved monitoring of arteriovenous (AV) fistulas and detecting complications before they become emergencies, PatenSee’s founders were the winners of MEDX’s 2019 entrepreneurial challenge, which it ran in cooperation with its strategic partners. The win was an accolade that came with a million-dollar investment and full incubation package. The company’s prestigious scientific advisory board, which includes key opinion leaders like acclaimed nephrologist Charmaine Lok, MD, is now also a distinguishing factor.
